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Abstract Background: The clini-
cal significance of nontuberculous
mycobacteria (NTM) pulmonary
infection in medical intensive care
unit (ICU) is still unclear. Materials
and methods: We conducted a ret-
rospective study in the medical ICUs
of a medical center in Taiwan from
January 1999 to June 2007. Patients
with NTM isolated from respiratory
specimens within 1 month before or
during the ICU course were identi-
fied. Those who fulfilled the
diagnostic criteria of NTM pulmon-
ary infection were identified and
compared with patients with NTM
colonization and control subjects who
were culture-negative for mycobac-
teria. Results: Among the 5,378
patients admitted to medical ICUs,
2,866 (53.3%) had received myco-
bacterial culture for respiratory
specimens. NTM were isolated from
169 (5.8%) patients. Of them, 47
(27.8%) were considered NTM pul-
monary infection. M. avium complex
and M. abscessus were the most
common pathogens. Within 100 days
after ICU admission, significantly
more patients with NTM infection
died than those with NTM coloniza-
tion and control subjects (47 vs. 8 vs.
14%, P \ 0.001). Twenty-one (49%)
patients with NTM pulmonary infec-
tion received anti-NTM treatment,
with four experiencing adverse
effects. Although statistically insig-
nificant, anti-NTM treatment was
associated with prolonged survival
for those who died in the ICU and
shorter ICU stay for those who sur-
vived the ICU course.
Conclusion: Our findings suggest
that NTM pulmonary infection seems
to associate with higher mortality in
medical ICUs. Anti-NTM treatment is
probably associated with a better
outcome. Therefore, keeping a high
suspicion when NTM is isolated and
using careful consideration when
starting anti-NTM treatment should
be emphasized.
Keywords Nontuberculous
mycobacteria  Pulmonary infection 
Intensive care unit
Introduction
Unlike Mycobacterium tuberculosis (Mtb), nontubercu-
lous mycobacteria (NTM) exists in the environment and
can be isolated from clinical specimens due to true
infection, colonization, or even contamination [1]. It is an
important clinical concern since the rate of NTM pul-
monary infection has increased over the last 10 years
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[2–4]. The reasons for this increase are not clear, but
probably result from an enlarged population of acquired
immunocompromised individuals, chronic lung disease,
and prolonged mechanical ventilation [2, 5–9]. In our
hospital, among the patients with acid-fast smear-positive
respiratory specimens in 2006, 35% were due to NTM
[10]. In fact, NTM pulmonary infection remains a diag-
nostic challenge even under the contemporary guidelines
of the American Thoracic Society [1]. Because the pres-
ence of NTM in respiratory specimens is not
pathognomonic for NTM infection, treatment is not
deemed necessary by every clinician [11]. Even in dis-
seminated NTM disease, a previous study revealed that
adequate treatment was not started until 130 days after
the initial visit [12]. However, the mortality rate can
exceed 50% within 5 years [11, 13, 14].
In patients with complicated and critical conditions,
such as those admitted to intensive care unit (ICU), the
clinical significance of NTM in respiratory specimens and
the prognostic impact of NTM pulmonary infection are
even more difficult to understand than in stable patients
[11, 15]. Therefore, we conducted a retrospective study
including all medical ICU patients with NTM being iso-
lated from respiratory specimens within a period of
8.5 years to evaluate the clinical significance of the
presence of NTM and compare the demographic charac-
teristics, clinical manifestations, and outcome in patients
with NTM pulmonary infection with those with NTM
colonization and control subjects whose respiratory
samples were culture-negative for mycobacteria.
Materials and methods
Subject of study
This study was conducted in National Taiwan University
Hospital, a tertiary-care referral center with 2,150 beds in
northern Taiwan, and was approved by the Institutional
Review Boards of the hospital. We reviewed the myco-
bacterial laboratory registry database and identified all
patients who had undergone mycobacterial culture for
respiratory specimens between January 1999 and June
2007. Among them, only those with the mycobacterial
culture performed within 1 month before or during
admission to medical ICUs were included for further
analysis. In our hospital, mycobacterial culture for
respiratory specimens is usually ordered in the following
three conditions: (1) typical radiographic findings of post-
primary pulmonary tuberculosis, i.e. patchy, poorly
defined consolidation particularly in the apical and pos-
terior segments of the upper lobes and with cavitation
[16]; (2) contact history of active tuberculosis [17]; or (3)
a poor clinical response to anti-bacterial antibiotics,
defined as no improvement of symptoms, radiographic
findings, or laboratory data within 3 days after antibiotics
[18]. Mycobacterial culture was performed as previously
described [19]. Mycobacterial species were identified by
using biochemical testing [20].
Selection criteria of patients
In this study, NTM pulmonary infection was considered
definite if all the following were met [1]: (1) at least two
respiratory specimens or one bronchial washing/brushing
sample being culture-positive for the same NTM species;
(2) presence of respiratory symptoms; (3) chest radiog-
raphy or computed tomography demonstrating new
patch(es) of consolidation, nodular infiltrates, cavitary
lesions, or multifocal bronchiectasis; and (4) no bacterial
pathogens being isolated from respiratory specimens at
the same time. NTM pulmonary infection was considered
probable if a patient fulfilled the second and third criteria
of definite NTM and had three respiratory specimens that
yielded the same NTM species, yet bacterial pathogens
were isolated at the same time. The definite and probable
groups were considered as NTM pulmonary infection.
Because the presence of NTM in respiratory samples can
result from environmental contamination, only patients
who fulfilled the first criterion of microbiology but were
not considered to have NTM pulmonary infection were
considered as NTM colonization (colonization group) [1].
Those who had a radiographic response to anti-bacterial
antibiotics were classified into NTM colonization even if
they had two respiratory samples that were culture-posi-
tive for the same NTM. For each patient with NTM
pulmonary infection, an age-, gender-, and APACHE II
score-matched control subject for whom mycobacterial
culture was performed during ICU admission for C3
respiratory samples with the results being all negative was
selected as control group.
Clinical data
The medical records were reviewed. The chest images
were noted as in our previous study [21]. Radiographi-
cally, presence of reticulonodular lesions compatible with
pulmonary fibrosis and multifocal bronchiectasis were
categorized as structural lung change. The adequacy of
anti-NTM treatment was judged according to the ATS
guidelines [1]. Patients were followed for 100 days after
ICU admission or until death or discharge from the
hospital.
Statistics
The inter-group differences were compared by using One-
Way ANOVA for numerical variables and chi-square
test for categorical variables. Adjustments for multiple
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comparisons were made by applying the Bonferonni
method. Survival curves within 100 days since ICU
admission for each class of variables were generated
using the Kaplan-Meier method and were compared using
the log-rank test. Variables having a significant difference
(P \ 0.05) were further tested by multivariate Cox pro-
portional hazard regression analysis.
Results
From January 1999 to June 2007, a total of 4,779 respi-
ratory specimens were culture-positive for NTM
(Table 1). During this period, a total of 5,378 patients
were admitted to our medical ICUs. Of them, 2,866
(53.3%) received mycobacterial culture of respiratory
specimens. NTM was isolated from 337 samples from 169
patients collected within 1 month before or during
admission to the medical ICUs. Of them, 47 (27.8%) had
NTM pulmonary infection (24 (14.2%) definite and 23
(13.6%) probable), and 25 (14.8%) had NTM coloniza-
tion. Mycobacterium avium complex was the most
common NTM species. The medical records were not
available for four patients with NTM pulmonary infection
and one in the colonization group. Therefore, a total of 43
patients with NTM pulmonary infection, 24 with NTM
pulmonary colonization, and another 43 age-, sex-, and
APACHE-II score-matched control subjects were further
investigated.
Clinical data
Statistically, no significant difference was noted in the
age, gender, and cause of ICU admission among the three
groups (Table 2). Previous tracheostomy was signifi-
cantly associated with the colonization group
(P \ 0.001). Structural lung change was predominantly
found in patients with NTM pulmonary infection
(P \ 0.001). Underlying co-morbid condition was more
frequent in the control group (P = 0.015). The most
common was malignancy in the NTM infection group, but
diabetes mellitus in the other two groups. HIV serostatus
was checked in 15 (35%), 10 (42%), and 10 (42%)
patients in the NTM infection, NTM colonization, and
control groups, respectively. The prevalence of HIV/
AIDS was not significantly different. Respiratory failure
was the most common indication for ICU admission in all
groups.
Chronic obstructive pulmonary disease (COPD) was
previously diagnosed in 10 (23.3%) patients with NTM
infection, 5 (20.8%) with NTM colonization, and 7
(16.3%) in the control group. The prevalence was not
significantly different among the three groups (P = 0.722).
Among patients with NTM infection, pulmonary function
test was performed in eight and revealed severe obstruc-
tive in 2, mild obstructive in 1, severe restrictive in 2,
moderate restrictive in 1, mixed obstructive and restrictive
defect in 1, and normal in the remaining one. Two patients
with NTM colonization underwent pulmonary function
test. The results were moderate obstructive in 1 and severe
restrictive in another. Univariate analysis revealed that
COPD did not associate with 100-days mortality in ICU
(P = 0.989).
Radiographically, there were significant differences
among the NTM infection, NTM colonization, and con-
trol groups in the prevalence of pulmonary consolidation
(31 (72%) vs. 11 (46%) vs. 32 (74%), P = 0.04), and
reticulonodular shadowing (23 (51%) vs. 2 (8%) vs. 4
(9%), P \ 0.001). Of the colonization group, 5 (21%)
patients had negative radiographic findings. In the NTM
infection group, 15 (35%) patients with reticulonodular
shadowing had cavitary lesions, whereas none in the other
two groups did.
At the beginning of the ICU course, the APACHE II
scores (Table 2), hemogram, and biochemistry, was not
significantly different among the NTM infection, NTM
colonization, and control groups. However, the control
group had the highest serum creatinine (1.2 ± 0.7 vs.
1.5 ± 1.4 vs. 2.3 ± 2.1 mg/dl, P = 0.009) and ratio of
arterial oxygen pressure divided by fraction of supplemental
Table 1 Number of isolates and patients with different NTM species in different clinical conditions during the 8.5 years
Mycobacterial
species
Numbers of NTM isolates and patients in intensive care unit All isolates in
our hospital
(N = 4,779)NTM infection NTM colonization Contamination
Isolates (N = 175) Patients (N = 47) Isolates (N = 65) Patients (N = 25) Patients (N = 97)
M. avium complex 67 (38.3%) 20 (42.6%) 27 (41.5%) 11 (44%) 33 (34%) 1,527 (31.9%)
M. abscessus 29 (16.6%) 8 (17%) 24 (36.9%) 8 (32%) 13 (13.4%) 898 (18.8%)
M. chelonae 34 (19.4%) 7 (14.9%) 4 (6.2%) 2 (8%) 2 (2.19%) 546 (11.4%)
M. fortuitum 10 (5.7%) 3 (6.4%) 7 (10.8%) 2 (8%) 13 (13.4%) 646 (13.5%)
M. kansasii 27 (15.4%) 7 (14.9%) 2 (3.1%) 1 (4%) 13 (13.4%) 310 (6.5%)
Others 8 (4.6%) 2 (4.3%) 1 (1.5%) 1 (4%) 23 (23.7%) 852 (17.8%)
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oxygen concentration (PaO2/FiO2) (252.2 ± 107 vs. 247.4
± 119 vs. 337 ± 168 mmHg, P = 0.001), and the lowest
arterial pressure of carbon dioxide (PaCO2) (53.8 ± 23.4
vs. 57.3 ± 26.9 vs. 40.2 ± 11.8 mmHg, P = 0.002).
Treatment and outcome
Table 3 and Fig. 1 show that the ICU-mortality and 100-
days mortality were highest in the NTM infection group.
Though statistically insignificant, the weaning rate was
highest in the control group. Univariate survival analysis
revealed that NTM pulmonary infection was associated
with a poor outcome (P = 0.008; hazard ratio (HR): 7.2;
95% CI: 1.7–30.8). To exclude the potential confounding
effect on NTM infection for survival, a multivariate Cox
regression analysis, containing other variables that were
significantly different among the three groups during uni-
variate analysis were performed. These variables included
NTM infection, structural lung change, tracheostomy, and
Table 2 Clinical characteristics
NTM infection (N = 43) NTM colonization (N = 24) Matched control (N = 43)
Age: year, mean (range) 69.7 (19–95) 67.7 (28–91) 69.8 (19–96)
Age [ 65 28 (65%) 16 (67%) 28 (65%)
Male gender 25 (58%) 20 (83%) 25 (58%)
Structural lung change*,a 25 (58%) 5 (21%) 5 (12%)
Having received tracheostomy* 7 (16%) 10 (42%) 4 (9%)
Underlying co-morbid condition* 19 (44%) 8 (33%) 29 (67%)
Malignancy 14 (33%) 2 (8%) 8 (19%)
AIDS 2 (5%) 2 (8%) 2 (5%)
Diabetes mellitus 2 (5%) 3 (13%) 11 (33%)
End-stage renal disease 1 (2%) 1 (4%) 4 (12%)
Cirrhosis of liver 2 (5%) 0 0
Autoimmune disease 0 0 4(9%)
Cause of ICU admission
Respiratory failure 35 (81%) 18 (75%) 29 (67%)
Pneumonia 32 (74%) 15 (63%) 28 (65%)
COPD with AE 1 (2 %) 3 (13%) 1 (2%)
Pneumothorax 2 (5%) 0 0
Sepsis, other than pneumonia 5 (12%) 2 (8%) 10 (23%)
Seizure 1 (2%) 1 (4%) 0
Attempted suicide 1 (2%) 0 0
DKA/NKHS 0 1 (4%) 2 (5%)
Cardiovascular disease 1 (2%) 2 (8%) 2 (5%)
APACHE II—initial (mean ± SD) 22.8 ± 6.9 21.6 ± 7.8 22.8 ± 7.8
APACHE II—24 h (mean ± SD) 20.2 ± 6.6 19.1 ± 8.0 21.2 ± 7.5
Data are no. (%), unless otherwise indicated
AIDS acquired immunodeficiency syndrome; APACHE acute
physiology and chronic healthy evaluation; COPD with AE chronic
obstructive pulmonary disease with acute exacerbation; DKA dia-
betic ketotic acidosis; NKHS non-ketotic hyperosmolar syndrome
* Significant difference (P \ 0.05) between the three groups
a Structural lung change was considered if reticulonodular lesions
compatible with pulmonary fibrosis and multifocal bronchiectasis
were present on chest images
Table 3 Outcome of patients
NTM infection NTM colonization
All (N = 24)
Control
All (N = 43)
Untreated (N = 22) Treated (N = 21)
Weaning rate 8 (n = 19, 42%) 6 (n = 16, 38%) 9 (n = 18, 50%) 27 (n = 37, 73%)
MV day: days ± SD 6.25 ± 3.1 10.2 ± 10.2 16.0 ± 9.6 11.33 ± 12.3
ICU-mortality* 5 (26%) 6 (29%) 2 (8%) 2 (5%)
ICU-stay: days ± SD 21.4 ± 15.7 22.4 ± 16.4 20.7 ± 19.3 18.0 ± 15.2
Survived: days ± SD 22.7 ± 16.4 18 ± 11.4 17 ± 14.8 18.0 ± 15.3
Dead: days ± SD 17.0 ± 13.7 33.3 ± 22.5 61 ± 21.2 18.1 ± 15.1
100-days mortality* 10 (45.6%) 10 (47.6%) 2 (8.3%) 6 (14%)
Data are no. (%), unless otherwise indicated
ICU intensive care unit; MV mechanical ventilation; NTM nontuberculous mycobacteria
* Significant difference (P \ 0.05) between NTM infection, NTM colonization and control groups
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underlying co-morbid conditions. The results revealed
NTM pulmonary infection still had significant prognostic
impact (P = 0.004; HR: 8.7; 95% CI: 2.0–38.5), and none
of the other three variables was an independent prognostic
factor (structural lung change: HR = 1.6, 95% CI: 0.7–3.7;
tracheostomy: HR = 0.9, 95% CI: 0.3–2.3; underlying co-
morbid condition: HR = 0.7, 95% CI: 0.3–1.5).
In the NTM infection group, mycobacterial culture for
respiratory samples was performed prior to ICU admis-
sion in 31 patients, and was positive for NTM in 13. The
13 patients had a higher 100-day mortality rate than the
30 patients from whom NTM was isolated after ICU
admission (61.5 vs. 40%, P = 0.025). More patients in the
latter had underlying co-morbid condition than in the
former (23 vs. 53%, P = 0.098). Other clinical charac-
teristics, such as APACHE II score (21.55 vs. 23.4),
albumin (3.28 vs. 3.08 g/dl), serum creatinine (1.0 vs.
1.3 mg/dl), and C-reactive protein (13.1 vs. 10.4 mg/dl)
were similar in the two subgroups.
Of the 22 patients in the NTM infection or NTM
colonization group who died within 100 days after ICU
admission, nine patients, including two belonging to the
colonization group, had definite causes of death other than
NTM infection. Another ten died of respiratory failure
due to refractory pneumonia with unknown pathogens.
The remaining three patients died of multi-organ failure,
one of them having M. avium-intracellular complex
(MAC) bacteremia. Among the ten patients with NTM
infection who were treated and died within 100 days after
ICU admission, all had multidrug-resistant enterobacte-
riae such as Pseudomonas aeruginosa or Acinetobacter
baumannii, defined as resistance to C2 classes of anti-
pseudomonal agents, or methicillin-resistant Staphylo-
coccus aureus, isolated from their respiratory samples
during the following hospital course.
Of the patients with NTM pulmonary infection,
treatment for NTM was prescribed in 21 (49%), and was
started 21.1 ± 28.3 days on average after ICU admis-
sion. Although statistically insignificant, anti-NTM
treatment was associated with prolonging survival for
those who died in the ICU and with shortening the ICU
stay for those who survived the ICU course (Table 3).
All eight patients with MAC infection were treated with
macrolides-containing regimens, with four not receiving
ethambutol. Four of ten patients who were treated for
rapid growing mycobacteria infection received macrolide
monotherapy. The remaining three received treatment
for M kansasii or M. terrae infection according to the
ATS guidelines. Five episodes of adverse effects were
reported in four patients, including one each for bone
marrow suppression, hepatitis, diarrhea, fever and blur-
red vision.
Discussion
The 5-year mortality rate has been reported to be around
34–69% in NTM pulmonary infection [11, 14, 22].
However, decision making for treating NTM is a big
clinical challenge because NTM are usually considered as
colonizers rather than true pathogens in the respiratory
tract. In addition, NTM pulmonary infection was usually
considered to have chronic indolent disease [1, 23].
Consequently, treatment for NTM is usually delayed. The
clinical significance and prognostic impact of NTM in
respiratory specimens of patients in medical ICUs is even
more obscure, because the issue has been discussed only
in few case reports [24–26]. Therefore, decision making
for treating NTM in critically-ill patients is extremely
difficult. This is probably the reason why anti-NTM
treatment was prescribed in only 49% of our NTM
infected patients, lower than that reported in non-critical
populations (65.5%) [11].
Though the total number of the mortality cases was not
sufficiently large for conducting a multivariate Cox pro-
portional hazard regression analysis including four
variables [27], our results revealed that NTM pulmonary
infection was probably associated with higher mortality in
medical ICUs, even after controlling the possible con-
founding factors. The reasons are not clear, but this is
probably because NTM pulmonary infection acts as an
underlying co-morbid condition, which in turn deteriorates
the pulmonary function and compromises the defense
mechanism of the lung, and is associated with difficult
eradicating of gram-negative organisms in airway [28].
Another possible explanation is that the prolonged antibi-
otic treatment including new fluoroquinolone and
aminoglycosides for NTM infection could probably induce
the emergency of multidrug-resistant P. aeruginosa or
A. baumannii later in the hospital course, which has been
Fig. 1 Survival curve for patients with NTM pulmonary infection,
colonization, or control group plotted using the Kaplan-Meier
method. Black dots represent patients who were still alive at the end
of the study
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documented to increase the infection-related mortality [29–
31]. However, these issues should be further confirmed.
In ICU patients with NTM pulmonary infection, our
analysis revealed that the presence of NTM in respiratory
samples prior to ICU admission was associated with a
worse survival. The finding that 60% (18 in 30) of those
with NTM isolated during ICU course did not have NTM
prior to ICU admission implies that most of them could be
in an earlier course of the NTM infection and probably
had better lung function and host defense.
Among non-critical patients with NTM isolated from
their respiratory specimens, the proportion of true infec-
tion was 20–25% in the 2000s [15, 32]. In our study,
NTM was isolated from respiratory specimens in 5.8% of
all patients admitted to our medical ICUs. Among them,
27.8% were considered infection rather than colonization
or contamination. The reasons for the enlarging propor-
tion of true infection are still unclear, but probably due to
the improvement of the culture technique for NTM and
the higher suspicion. In addition, a growing population of
chronic lung disease, prolonged mechanical ventilation
and immune dysfunction due to the underlying condition,
such as AIDS and malignancy has been proposed [2, 6–9].
This finding emphasizes that careful interpretation of the
results of mycobacterial culture for respiratory specimens
and repeated culture surveillance are extremely important
in this population.
The most common species in NTM pulmonary infec-
tion were different among different studies; M. kansasii in
England and Wales, M. xenopi in Southeast England,
M. avium complex (MAC) in the United States, Japan, and
South Korea, and MAC and M. abscessus in our patients
[2, 4, 15, 33–35]. In contrast to previous reports, a higher
proportion of rapid growing mycobacteria were found in
our series (38 vs. 10% in the United States and less than
5% in Japan) [4, 33, 35]. In our study, the presence of
M. chelonae isolate in the respiratory tract was more likely
to be a true infection than other species (64 vs. 17–34%)
although statistically insignificant. Therefore, under-
standing the local epidemiology is important in the
management of patients with NTM isolated from their
respiratory specimens.
Radiographically, a much smaller proportion (51%) of
our patients with NTM infection had reticulonodular
opacity than those (70–90%) in previous reports [15, 36,
37]. In contrast, there was a markedly higher proportion
(72%) of our patients with NTM infection having pul-
monary consolidation than that (30%) in the study
performed by Koh et al. [15]. One possible explanation is
that about half of our patients with NTM infection had
underlying immunocompromised conditions, probably
predisposing to other radiographic manifestations, as it
has been reported that only 6% of AIDS patient with
NTM pulmonary infection demonstrated typical reticul-
onodular opacity [38]. In addition, decreased serum
albumin level, immobilization, positive pressure ventila-
tion, and severe pulmonary inflammation in critical illness
all predispose to the accumulation of pleural effusion,
leading to misinterpretation for the pulmonary lesions as
consolidation.
Some studies on non-critical patients have revealed
that anti-NTM treatment did not improve the outcome
[11, 14]. It might be attributed to the small number of
patients (31 and 42 in the two studies, respectively) and
the presence of confounding factors, such as underlying
co-morbid conditions. In addition, the susceptibility tests
were usually not routinely performed [39] and the che-
motherapy regimens for all NTM species were impossible
to be standardized. In contrast, studies on AIDS patients
with non-disseminated NTM disease have showed that
anti-NTM treatment was beneficial in 2-year follow-up
[38, 40]. In our study, treatment for NTM infection also
did not improve the outcome. However, among the
patients with NTM infection who survived the ICU
course, those receiving anti-NTM treatment was associ-
ated with a shorter stay in ICU. In addition, among the
patients with NTM infection who died in the ICU, anti-
NTM treatment was associated with prolong survival
(Table 3). Further large-scale prospective studies are
necessary to investigate the impact of anti-NTM treat-
ment and to clarify possible confounding factors.
If anti-NTM treatment does improve the outcome of
patients in ICU, keeping a high suspicion, establishing the
diagnosis early, and starting adequate treatment promptly
become very important. Several clinical characteristics
were associated with NTM pulmonary infection, includ-
ing structural lung change without tracheostomy,
radiographically reticulonodular shadowing with cavita-
tion, and isolation of M. chelonae. For those patients,
NTM pulmonary infection should be suspected once
having NTM isolated from their respiratory specimens.
Our study has several limitations. First, due to the
small number of patients, we could not make any firm
conclusions, especially in identifying the reasons for the
high mortality rate in NTM infected patients and in ana-
lyzing the importance of anti-NTM treatment. Second, in
this retrospective study, the number of patients with NTM
infection could be underestimated because mycobacterial
cultures were performed in 53.3% of ICU patients. In
addition, structural lung change that was only mild and
beyond the detection threshold of the chest radiography
will be missed. Large scale prospective study is needed
for further investigation.
Conclusion
Our findings suggest that NTM pulmonary infection
probably increases the mortality of the medical ICU
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patients. Anti-NTM treatment could possibly improve the
outcome. At present, keeping a high suspicion when NTM
is isolated and using careful consideration when starting
anti-NTM treatment should be emphasized.
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